Get the Stockscreener App
15.10
0.67%
0.10
After Hours:
15.10
Bausch Lomb Corp stock is traded at $15.10, with a volume of 1.10M.
It is up +0.67% in the last 24 hours and up +0.67% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$15.00
Open:
$14.9
24h Volume:
1.10M
Relative Volume:
2.07
Market Cap:
$5.31B
Revenue:
$4.89B
Net Income/Loss:
$-263.00M
P/E Ratio:
-19.52
EPS:
-0.7734
Net Cash Flow:
$-167.84M
1W Performance:
-8.09%
1M Performance:
+0.67%
6M Performance:
+28.40%
1Y Performance:
-23.58%
1-Day Range:
$14.69
$15.21
1-Week Range:
$14.69
$16.81
52-Week Range:
$10.45
$20.71
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
15.10 | 5.31B | 4.89B | -263.00M | -167.84M | -0.7734 |
|
BDX
Becton Dickinson Co
|
192.33 | 54.74B | 21.84B | 1.68B | 2.67B | 5.8322 |
|
ALC
Alcon Inc
|
75.78 | 37.63B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
ISRG
Intuitive Surgical Inc
|
546.77 | 193.81B | 9.61B | 2.77B | 2.27B | 7.555 |
|
RMD
Resmed Inc
|
246.22 | 35.72B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
COO
The Cooper Companies, Inc.
|
72.20 | 14.19B | 3.93B | 415.40M | 384.70M | 2.06 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Initiated | Goldman | Neutral |
| May-02-25 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
Is Bausch + Lomb Corporation stock dividend growth reliableJuly 2025 Rallies & Long-Term Investment Growth Plans - newser.com
Bausch + Lomb to Engage at Citi Global Healthcare Conference - TipRanks
What consensus target says about Bausch + Lomb Corporation (S2L) stock2025 Major Catalysts & Entry Point Confirmation Signals - newser.com
Is Bausch + Lomb Corporation (S2L) stock worth buying before Fed actionWeekly Investment Report & Reliable Entry Point Alerts - newser.com
Bausch + Lomb to Participate in Citi Global Healthcare Conference - MarketScreener
Bausch + Lomb (NYSE: BLCO) leaders to speak at 2025 Citi Global Healthcare Conference - Stock Titan
Is Bausch + Lomb Corporation stock a buy for dividend growthWeekly Investment Report & Verified Stock Trade Ideas - newser.com
Will Bausch + Lomb Corporation stock announce special dividendWeekly Risk Summary & Weekly High Potential Stock Alerts - newser.com
Can Bausch + Lomb Corporation (S2L) stock sustain double digit ROEJuly 2025 PreEarnings & Weekly High Momentum Picks - newser.com
Why global investors buy Bausch + Lomb Corporation stock2025 Big Picture & Accurate Entry and Exit Point Alerts - newser.com
How Bausch + Lomb Corporation (S2L) stock responds to bond marketJuly 2025 Spike Watch & Low Risk High Win Rate Picks - newser.com
Does Bausch + Lomb Corporation (S2L) stock trade below intrinsic valueMarket Rally & Verified Momentum Stock Watchlist - newser.com
Bausch + Lomb’s Rochester site positioned as key hub for next-gen contact lens production - Rochester Business Journal
Short interest data insights for Bausch + Lomb Corporation2025 Key Lessons & Weekly Top Gainers Trade List - newser.com
Real time breakdown of Bausch + Lomb Corporation stock performance2025 Risk Factors & Daily Stock Trend Watchlist - newser.com
How strong is Bausch + Lomb Corporation stock revenue growthEarnings Recap Report & AI Driven Stock Price Forecasts - newser.com
Can Bausch + Lomb Corporation stock resist sector downturns2025 Market Trends & Community Supported Trade Ideas - newser.com
Using data models to predict Bausch + Lomb Corporation stock movementJuly 2025 Drop Watch & Intraday High Probability Alerts - newser.com
Is Bausch + Lomb (NYSE:BLCO) Undervalued? A Fresh Look at Its Current Valuation - Yahoo Finance
Technical analysis overview for Bausch + Lomb Corporation stockJuly 2025 Spike Watch & Weekly Chart Analysis and Trade Guides - newser.com
What margin trends mean for Bausch + Lomb Corporation stockStop Loss & High Accuracy Trade Signal Alerts - newser.com
(BLCO) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $17 to $17 - 富途牛牛
What is the fair value estimate for Bausch + Lomb Corporation (S2L) stock in 2025Market Volume Summary & Stock Portfolio Risk Management - newser.com
Applying big data sentiment scoring on Bausch + Lomb CorporationStop Loss & Momentum Based Trading Signals - newser.com
Earnings visualization tools for Bausch + Lomb Corporation2025 Volume Leaders & Weekly Stock Performance Updates - newser.com
(BLCO) Stock Market Analysis (BLCO:CA) - news.stocktradersdaily.com
Wells Fargo Maintains Bausch + Lomb (BLCO) Equal-Weight Recommendation - Nasdaq
Jefferies raises Bausch & Lomb stock price target to $20 on strong growth outlook - Investing.com Nigeria
Bausch & Lomb stock price target raised to $19 by RBC on margin outlook - Investing.com Nigeria
Custom strategy builders for tracking Bausch + Lomb CorporationJuly 2025 Pullbacks & Daily Stock Trend Watchlist - newser.com
Cautious Hold Rating on Bausch + Lomb: Awaiting Catalysts for Stock Valuation Boost - TipRanks
A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $13 to $19 - 富途牛牛
RBC Raises Price Target on Bausch + Lomb to $19 From $17, Keeps Outperform Rating - MarketScreener
Needham maintains Hold rating on Bausch & Lomb stock amid pipeline potential - Investing.com UK
Why Bausch + Lomb Corporation stock could see breakout soonMarket Sentiment Review & Safe Swing Trade Setup Alerts - newser.com
Bausch + Lomb Sets Ambitious Growth Targets At Investor Day - Finimize
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.39%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):